Grindeks informs that the manufactured medication by the company Amitriptyline-Grindeks has received an award for “The best anti-depressant in somatic practice” in the international award ceremony “Medicus Pharmaque 2012” in Russia. The prestigious award ceremony took place in the framework of the international health care conference “Medicine 2012”.

In order to determine the best medications, a voting was organized, in which any Russian doctor could express her or his view. In the voting the most popular medicinal preparations in Russia, which have also important sales, were included. Thus, the results of the voting reflect the view of medical practitioners and their daily experiences using a variety of medications in the treatment of various diseases.

In the award ceremony Amitriptyline-Grindeks important role in the treatment of depression was highlighted, with which, by the experts` opinion, the word “antidepressant” is associated most directly. Also available medication price category for the patients had been evaluated. Amitriptyline-Grindeks is a classic antidepressant with a broad spectrum of effect, with which the newest depression treatment medications are compared.

Depression is one of the most common mental illnesses. European statistics show that during life with the depression encounter 13.4%, and during 12-month period 4.1% of the population. There is a presumption that during life with the condition qualifying for depression criteria face up to 10% of men and 20% of women.*

Grindeks Chairman of the Board Juris Bundulis: “Central Nervous System medications is one of Grindeks key therapeutic areas. Several medications of this group are the success stories of the company, and also the recognition that received among physicians popular product Amitriptyline-Grindeks is noteworthy evaluation not only for this medication, but also for the company as a whole. It is a testimony that the company is valued and that professionals trust Grindeks medications. There is a public opinion that depression is one of the major diseases, and also the statistics confirm this. Therefore, Grindeks is pleased that, thanks to our medications, doctors can help patients to eliminate health problems and improve quality of life.”

Amitriptyline-Grindeks is one of the most recognizable central nervous system affecting prescription medications of Grindeks used for depression treatment. CNS group medications` proportion of the total turnover was 10.3% in 2011.

* Information from the Latvian Psychiatric Association prepared guidelines “Course of depression and treatment options”.

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. Its main fields of action are: research, development, manufacturing and sale of original products, generics and active pharmaceutical ingredients. The Group of Grindeks consists of four subsidiary companies in Latvia, Estonia and Russia, as well representative offices in ten countries.

Grindeks specializes in the heart and cardiovascular, CNS and anti-cancer medication therapeutic groups. A range of products covers a successful combination of original products and generics, with the original products Mildronate® and Ftorafur® and more than 100 forms of effective and safe generics included therein. Currently Grindeks produces 22 active pharmaceutical ingredients.

Products of the company are exported to 50 countries and its export comprises more than 95% of the total turnover. The main markets are: Russia and other CIS countries, the Baltic States, Germany and the Netherlands. In 2010 The Ministry of Economics of Republic of Latvia and Investment and Development Agency of Latvia awarded Grindeks as the most export potential company of Latvia.
During the last years the company realized many considerable investment projects in purpose to increase production capacity and develop infrastructure and invested 32.7 million lats within five years.

JSC Grindeks shares are listed in the Official List of „Nasdaq OMX Riga”. Major shareholders of JSC Grindeks are Kirovs Lipmans – 33.29%, Anna Lipmane – 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda Banken” – 10.94%, “Swedbank” AS Clients Account – 8.28%

Further information:

Laila Kļaviņa
Head of the Communications Department, JSC Grindeks
Phones: (+371) 67083370, (+371) 29256012
Fax: (+371) 67083505
laila.klavina@grindeks.lv